• 1
    Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 11061118.
  • 2
    Watkins PB. Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 2005; 33: 15.
  • 3
    Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 24572471.
  • 4
    Nicholson G, Hall GM. Diabetes mellitus: new drugs for a new epidemic. Br J Anaesth 2011; 107: 6573.
  • 5
    Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 2011; 342: d1309.
  • 6
    Rosen CJ. Revisiting the rosiglitazone story – lessons learned. N Engl J Med 2010; 363: 803806.
  • 7
    Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 13641379.
  • 8
    Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol Metab 2012; 23: 205215.
  • 9
    Barnett AH. Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vasc Health Risk Manag 2009; 5: 141151.
  • 10
    Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 2010; 70: 19451961.
  • 11
    Aronoff S, Rosenblatt S, Braithwaite S et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose–response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23: 16051611.
  • 12
    Bolli G, Dotta F, Colin L, Minic B, Goodman M. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab 2009; 11: 589595.
  • 13
    Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005; 22: 399405.
  • 14
    Tan MH, Baksi A, Krahulec B et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005; 28: 544550.
  • 15
    Russell-Jones D, Cuddihy RM, Hanefeld M et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012; 35: 252258.
  • 16
    Tan MH, Johns D, Strand J et al. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Diabet Med 2004; 21: 859866.
  • 17
    Charbonnel B, Schernthaner G, Brunetti P et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005; 48: 10931104.
  • 18
    Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 24272443.
  • 19
    Petrie JR, Adler A, Vella S. What to add in with metformin in type 2 diabetes? QJM 2011; 104: 185192.
  • 20
    Knowler WC, Hamman RF, Edelstein SL et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54: 11501156.
  • 21
    Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 10961105.
  • 22
    Xiang AH, Peters RK, Kjos SL et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006; 55: 517522.
  • 23
    Defronzo RA, Banerji M, Bray GA et al. Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord 2009; 9: 17.
  • 24
    Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 20052012.
  • 25
    DeFronzo RA. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am J Med 2010; 123(Suppl. 3): S38S48.
  • 26
    Diani AR, Sawada G, Wyse B, Murray FT, Khan M. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab 2004; 286: E116E122.
  • 27
    Lin CY, Gurlo T, Haataja L, Hsueh WA, Butler PC. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3'-kinase-dependent pathway. J Clin Endocrinol Metab 2005; 90: 66786686.
  • 28
    Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007; 292: E871E883.
  • 29
    Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 27842791.
  • 30
    Bajaj M, Suraamornkul S, Pratipanawatr T et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003; 52: 13641370.
  • 31
    Kovacs P, Stumvoll M. Fatty acids and insulin resistance in muscle and liver. Best Pract Res Clin Endocrinol Metab 2005; 19: 625635.
  • 32
    Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008; 77: 289312.
  • 33
    Yu JG, Javorschi S, Hevener AL et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51: 29682974.
  • 34
    Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24: 278301.
  • 35
    Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002; 32(Suppl. 3): 2434.
  • 36
    Lupi R, Del Guerra S, Marselli L et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 2004; 286: E560E567.
  • 37
    Dubois M, Pattou F, Kerr-Conte J et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 2000; 43: 11651169.
  • 38
    Decker M, Hofflich H, Elias AN. Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis. Diabetes Obes Metab 2008; 10: 617625.
  • 39
    Glass CK, Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010; 10: 365376.
  • 40
    Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000; 106: 523531.
  • 41
    Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 21652168.
  • 42
    Law RE, Goetze S, Xi XP et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000; 101: 13111318.
  • 43
    Sugawara A, Takeuchi K, Uruno A et al. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 2001; 142: 31253134.
  • 44
    Saremi A, Schwenke DC, Buchanan TA et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2013; 33: 393399.
  • 45
    Zhang L, Chawla A. Role of PPARgamma in macrophage biology and atherosclerosis. Trends Endocrinol Metab 2004; 15: 500505.
  • 46
    Yue TL, Bao W, Gu JL et al. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005; 54: 554562.
  • 47
    Luo Y, Yin W, Signore AP et al. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 2006; 97: 435448.
  • 48
    Ye Y, Lin Y, Atar S et al. Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. Am J Physiol Heart Circ Physiol 2006; 291: H1158H1169.
  • 49
    Marx N, Walcher D. Vascular effects of PPARgamma activators - from bench to bedside. Prog Lipid Res 2007; 46: 283296.
  • 50
    Schernthaner G, Chilton RJ. Cardiovascular risk and thiazolidinediones – what do meta-analyses really tell us? Diabetes Obes Metab 2010; 12: 10231035.
  • 51
    Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010; 170: 11911201.
  • 52
    Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 11801188.
  • 53
    Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 2008; 10: 12211238.
  • 54
    Selvin E, Bolen S, Yeh HC et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008; 168: 20702080.
  • 55
    Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 25722581.
  • 56
    Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 15611573.
  • 57
    Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 12791289.
  • 58
    Erdmann E, Dormandy JA, Charbonnel B et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49: 17721780.
  • 59
    Wilcox R, Bousser MG, Betteridge DJ et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38: 865873.
  • 60
    Tzoulaki I, Molokhia M, Curcin V et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009; 339: b4731.
  • 61
    Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 2012; 97: 46054612.
  • 62
    Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 15471554.
  • 63
    Ferrannini E, Betteridge DJ, Dormandy JA et al. High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive. Diabetes Obes Metab 2011; 13: 759764.
  • 64
    Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 2008; 31: 16721678.
  • 65
    Davidson M, Meyer PM, Haffner S et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation 2008; 117: 21232130.
  • 66
    Qin S, Liu T, Kamanna VS, Kashyap ML. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha. Arterioscler Thromb Vasc Biol 2007; 27: 24282434.
  • 67
    Sakamoto J, Kimura H, Moriyama S et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000; 278: 704711.
  • 68
    Vu-Dac N, Chopin-Delannoy S, Gervois P et al. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem 1998; 273: 2571325720.
  • 69
    Shu H, Wong B, Zhou G et al. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun 2000; 267: 345349.
  • 70
    Szapary PO, Bloedon LT, Samaha FF et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 182188.
  • 71
    Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 2009; 339: b2942.
  • 72
    Geng DF, Jin DM, Wu W, Wang Z, Wang JF. Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: a meta-analysis of randomized controlled trials. Atherosclerosis 2009; 202: 521528.
  • 73
    Nishio K, Kobayashi Y. Different effects of thiazolidinediones on target vessel revascularization with bare metal stents: a meta-analysis. Cardiovasc Revasc Med 2010; 11: 227231.
  • 74
    Garcia-Garcia HM, Garg S, Brugaletta S et al. Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History). Int J Cardiovasc Imaging 2012; 28: 455465.
  • 75
    Hong SJ, Kim ST, Kim TJ et al. Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation. Arterioscler Thromb Vasc Biol 2010; 30: 26552665.
  • 76
    Van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2011; 4: 249263.
  • 77
    Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 16751685.
  • 78
    Rakoski MO, Singal AG, Rogers MA, Conjeevaram H. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2010; 32: 12111221.
  • 79
    Mahady SE, Webster AC, Walker S, Sanyal A, George J. The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. J Hepatol 2011; 55: 13831390.
  • 80
    Ratziu V, Giral P, Jacqueminet S et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100110.
  • 81
    Ratziu V, Charlotte F, Bernhardt C et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010; 51: 445453.
  • 82
    Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weight gain in type 2 diabetes mellitus. Diabetes Obes Metab 2007; 9: 386393.
  • 83
    Raskin P, Rendell M, Riddle MC et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 12261232.
  • 84
    Basu A, Jensen MD, McCann F, Mukhopadhyay D, Joyner MJ, Rizza RA. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006; 29: 510514.
  • 85
    Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89: 463478.
  • 86
    Balas B, Belfort R, Harrison SA et al. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol 2007; 47: 565570.
  • 87
    Adams M, Montague CT, Prins JB et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100: 31493153.
  • 88
    Tolman KG. The safety of thiazolidinediones. Expert Opin Drug Saf 2011; 10: 419428.
  • 89
    Fuchtenbusch M, Standl E, Schatz H. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2000; 108: 151163.
  • 90
    Yang T, Soodvilai S. Renal and vascular mechanisms of thiazolidinedione-induced fluid retention. PPAR Res 2008; 2008: 943614.
  • 91
    Borsting E, Cheng VP, Glass CK, Vallon V, Cunard R. Peroxisome proliferator-activated receptor-gamma agonists repress epithelial sodium channel expression in the kidney. Am J Physiol Renal Physiol 2012; 302: F540F551.
  • 92
    Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003; 108: 29412948.
  • 93
    Ryan EH Jr, Han DP, Ramsay RC et al. Diabetic macular edema associated with glitazone use. Retina 2006; 26: 562570.
  • 94
    Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med 2012; 172: 10051011.
  • 95
    Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol 2009; 147: 583586 e1.
  • 96
    Motola D, Piccinni C, Biagi C et al. Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. Drug Saf 2012; 35: 315323.
  • 97
    Ambrosius WT, Danis RP, Goff DC Jr et al. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol 2010; 128: 312318.
  • 98
    Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 21252135.
  • 99
    Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med 2007; 357: 2838.
  • 100
    Erdmann E, Charbonnel B, Wilcox RG et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007; 30: 27732778.
  • 101
    Dormandy J, Bhattacharya M, de Bruyn ARV, Investigators P. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes an overview of data from PROactive. Drug Saf 2009; 32: 187202.
  • 102
    Graham DJ, Ouellet-Hellstrom R, MaCurdy TE et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304: 411418.
  • 103
    Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, Williams LK. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95: 592600.
  • 104
    Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM. Thiazolidinediones and fractures in men and women. Arch Intern Med 2009; 169: 13951402.
  • 105
    Meymeh RH, Wooltorton E. Diabetes drug pioglitazone (Actos): risk of fracture. Can Med Assoc J 2007; 177: 723724.
  • 106
    Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. Can Med Assoc J 2009; 180: 3239.
  • 107
    Grey A, Bolland M, Gamble G et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007; 92: 13051310.
  • 108
    Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008; 93: 16961701.
  • 109
    Colhoun HM, Livingstone SJ, Looker HC et al. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 2012; 55: 29292937.
  • 110
    Mieczkowska A, Basle MF, Chappard D, Mabilleau G. Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism. J Biol Chem 2012; 287: 2351723526.
  • 111
    Lecka-Czernik B, Gubrij I, Moerman EJ et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 1999; 74: 357371.
  • 112
    Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002; 143: 23762384.
  • 113
    Mabilleau G, Mieczkowska A, Edmonds ME. Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression. Diabet Med 2010; 27: 925932.
  • 114
    Lewis JD, Ferrara A, Peng T et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916922.
  • 115
    Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012; 55: 19531962.
  • 116
    Azoulay L, Yin H, Filion KB et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case–control study. BMJ 2012; 344: e3645.
  • 117
    Kermode-Scott B. Meta-analysis confirms raised risk of bladder cancer from pioglitazone. BMJ 2012; 345: e4541.
  • 118
    Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 2012; 55: 14621472.
  • 119
    Govindarajan R, Ratnasinghe L, Simmons DL et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007; 25: 14761481.
  • 120
    Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 2012; 12: 181195.
  • 121
    Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 2004; 5: 419429.
  • 122
    Sato K, Awasaki Y, Kandori H et al. Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats. Toxicol Appl Pharmacol 2011; 251: 234244.
  • 123
    Anderson SL, Marrs JC. Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother 2012; 46: 590598.
  • 124
    Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773795.
  • 125
    DeFronzo RA, Tripathy D, Schwenke DC et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364: 11041115.
  • 126
    Gale EA. Who needs the diabetes specialist physician? Diabetologia 2008; 51: 700702.
  • 127
    Brown JP, Josse RG for the Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002; 167(Suppl. 10): S1S34.